Result of AGM

RNS Number : 4748M

IXICO plc

21 January 2021

 

IXICO plc

("IXICO" or the "Company")

Results of AGM

IXICO plc (AIM: IXI), the AI digital technologies company serving neuroscience, announces that all resolutions put forward to its Annual General Meeting held earlier today were duly passed and the votes cast were as follows:

Resolution	Description	Total Votes For	% Votes	Total Votes Against	Withheld
1	Reports and Accounts	30,185,052	99.95%	15,600	400
2	Re-election of Directors
	Re-election of Mark Warne	30,185,152	99.95%	15,900	0
	Re-election of John Bradshaw	30,185,452	99.95%	15,600	0
3	Re-appointment of Auditors	30,065,960	99.57%	128,100	6,992
4	Allotment of Securities	30,180,960	99.94%	17,100	2,992
5	Disapply Pre-Emption Provisions	30,180,010	99.94%	18,050	2,992
6	Amendment of rule 3.6.1 of the Company's 2014 EMI Share Option Plan	30,165,610	99.89%	33,350	1,992

For further information please contact:

IXICO plc			[phone]
Giulio Cerroni, Chief Executive Officer Grant Nash, Chief Financial Officer
Cenkos Securities PLC (Nominated adviser and sole broker)				[phone]
Giles Balleny / Max Gould (Corporate Finance)
Michael F Johnson / Russell Kerr (Sales)
Walbrook PR Ltd	[phone]
Paul McManus /  Lianne Cawthorne /		[e-mail]
Alice Woodings

About IXICO

IXICO is dedicated to delivering insights in neuroscience. Our purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience and our goal is to be a leading proponent of artificial intelligence in medical image analysis. We will achieve this by developing and deploying breakthrough data analytics, at scale, through our remote access technology platform, to improve the return on investment in drug development and reduce risk and uncertainty in clinical trials for our pharmaceutical clients.

More information is available on   www.IXICO.com   and follow us on Twitter @IxicOplc  

 

END

 

 

RAGDKDBPKBKDFDB